Trial Profile

Phase I trial of single doses of IMO 3100 in healthy volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMO 3100 (Primary)
Indications Hyperlipidaemia; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
Focus Adverse reactions
Sponsors Aceragen

Most Recent Events

05 Apr 2011 Results from this trial have been presented in an Idera Pharmaceuticals media release.
15 Feb 2011 Status changed from active, no longer recruiting to completed.
08 Jun 2010 Preliminary results have been announced by Idera Pharmaceuticals in a media release. The company plans to present detailed results at a scientific meeting in the fourth quarter of 2010.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com